NEW YORK--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) announced data from preclinical evaluation of the company’s drug candidate INNO-206, a doxorubicin prodrug for treatment of a variety of tumor types. Researchers found that INNO-206, a form of doxorubicin that attaches to circulating albumin and becomes activated once located at the tumor site, is much better tolerated in animal models than doxorubicin alone, a commonly prescribed chemotherapeutic agent. Data was presented today at the American Association for Cancer Research 2007 Annual Meeting in Los Angles, CA.
